Q2 Earnings Forecast for Septerna Issued By HC Wainwright

Septerna, Inc. (NASDAQ:SEPN - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Septerna in a note issued to investors on Monday, June 23rd. HC Wainwright analyst R. Selvaraju anticipates that the company will earn $0.09 per share for the quarter. HC Wainwright has a "Buy" rating and a $26.00 price objective on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna's Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.68 EPS, FY2025 earnings at $1.01 EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.46) EPS.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The business had revenue of $0.22 million for the quarter.

Several other analysts also recently commented on SEPN. Wells Fargo & Company increased their price objective on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Friday, May 16th. Cantor Fitzgerald raised their price target on shares of Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Stock Up 1.7%

Shares of NASDAQ SEPN opened at $10.71 on Wednesday. Septerna has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The firm's 50-day simple moving average is $8.65 and its 200 day simple moving average is $11.59.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC bought a new stake in shares of Septerna during the 4th quarter worth $25,000. New York State Common Retirement Fund purchased a new stake in Septerna during the fourth quarter worth about $32,000. Legal & General Group Plc bought a new stake in Septerna in the fourth quarter worth about $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna in the fourth quarter valued at about $45,000. Finally, BNP Paribas Financial Markets purchased a new position in Septerna in the fourth quarter valued at approximately $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.